Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) – Pipeline Review, H2 2016’, provides in depth analysis on Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted pipeline therapeutics.

The report provides comprehensive information on the Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C)

The report reviews Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics and enlists all their major and minor projects

The report assesses Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Egis Gyogyszergyar Nyrt

Johnson & Johnson

Otsuka Holdings Co Ltd

SK Biopharmaceuticals Co Ltd

TearSolutions LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) Overview 6

Therapeutics Development 7

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Products under Development by Stage of Development 7

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Products under Development by Therapy Area 8

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Products under Development by Indication 9

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Products under Development by Companies 12

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Companies Involved in Therapeutics Development 21

Egis Gyogyszergyar Nyrt 21

Johnson & Johnson 22

Otsuka Holdings Co Ltd 23

SK Biopharmaceuticals Co Ltd 24

TearSolutions LLC 25

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Drug Profiles 26

brexpiprazole - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Egis-11150 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Lacripep - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

ORM-12741 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

SKL-PSY - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Dormant Projects 37

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Discontinued Products 38

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Featured News & Press Releases 39

Sep 23, 2016: U.S. FDA Approves Labeling Update of REXULTI (brexpiprazole) for maintenance treatment of Schizophrenia 39

May 16, 2016: Otsuka to Present Data on Brexpiprazole at American Psychiatric Association Annual Meeting 39

Feb 08, 2016: U.S. FDA Accepts for Review Otsuka and Lundbeck’s sNDA Filing for Labeling Update of REXULTI (Brexpiprazole) for Maintenance Treatment of Schizophrenia 40

Jul 11, 2015: FDA approves Rexulti (brexpiprazole) as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia 40

May 12, 2015: Otsuka and Lundbeck to Present Data on Investigational Compound Brexpiprazole in Schizophrenia and Major Depressive Disorder at American Psychiatric Association Annual Meeting 41

Apr 17, 2015: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry 42

Dec 11, 2014: Otsuka And Lundbeck's Brexpiprazole Demonstrates Statistically Significant Effects In New Phase III Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting 43

Dec 10, 2014: Otsuka And Lundbeck Present Phase III Data on Brexpiprazple As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting 44

Sep 24, 2014: U.S. FDA Accepts Otsuka and Lundbeck's Filing for Review of Brexpiprazole for the Treatment of Schizophrenia and as Adjunctive Therapy for the Treatment of Major Depression 46

Jul 14, 2014: Otsuka and Lundbeck Submit New Drug Application in The Us for Brexpiprazole for The Treatment of Schizophrenia and as Adjunctive Therapy for The Treatment of Major Depressive Disorder 47

Mar 03, 2014: Investigational compound Brexpiprazole met primary and secondary study endpoints in phase III clinical trial in major depressive disorder 48

Jan 24, 2014: Otsuka and Lundbeck to Present New Data on Brexpiprazole in Major Depressive Disorder at European Psychiatry Association 2014 Congress 48

Mar 21, 2013: Orion Presents Promising Phase II Data For New Alzheimer's Disease Drug At AAN Annual Meeting 49

Mar 11, 2013: New Add-On Drug May Improve Memory In People With Moderate Alzheimer's Disease, Study Shows 50

May 15, 2011: Otsuka Pharmaceutical Announces Results From Phase II Study Of Investigational Product OPC-34712 As Adjunctive Therapy In Adults With Major Depressive Disorder 50

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Egis Gyogyszergyar Nyrt, H2 2016 21

Pipeline by Johnson & Johnson, H2 2016 22

Pipeline by Otsuka Holdings Co Ltd, H2 2016 23

Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 24

Pipeline by TearSolutions LLC, H2 2016 25

Dormant Projects, H2 2016 37

Discontinued Products, H2 2016 38

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Mechanism of Actions, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports